Journal:Cell:1

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
<StructureSection load='1dq8' size='500' side='right' scene='User:David_Canner/Workbench/Opening/2' caption='Solved Structures of IFNAR1/2/IFN Complexes'>
<StructureSection load='1dq8' size='500' side='right' scene='User:David_Canner/Workbench/Opening/2' caption='Solved Structures of IFNAR1/2/IFN Complexes'>
=== Structural linkage between ligand discrimination and receptor activation by type I interferons ===
=== Structural linkage between ligand discrimination and receptor activation by type I interferons ===
-
<big>Christoph Thomas, Ignacio Moraga, Doron Levin, Peter O. Krutzik, Yulia Podoplelova, Angelica Trejo, Choongho Lee, Ganit Yarden, Susan Vleck, Jeffrey S. Glenn, Garry P. Nolan, Jacob Piehler, Gideon Schreiber, K. Christopher Garcia</big><ref>no reference</ref>
+
<big>Christoph Thomas, Ignacio Moraga, Doron Levin, Peter O. Krutzik, Yulia Podoplelova, Angelica Trejo, Choongho Lee, Ganit Yarden, Susan E. Vleck, Jeffrey S. Glenn, Garry P. Nolan, Jacob Piehler, Gideon Schreiber, K. Christopher Garcia</big><ref>no reference</ref>
<hr/>
<hr/>
<b>Molecular Tour</b><br>
<b>Molecular Tour</b><br>
-
IFNs were the first cytokines discovered more than half a century ago as an agent that interfered with viral infection. Since then, IFNs have been established as pleiotropic, multifunctional proteins in the early immune response, exhibiting pronounced antiproliferative effects on cells, in addition to their strong immunomodulatory and antiviral activity. Due to their potency and diverse biological activities, IFNs are used for the treatment of several human diseases, including hepatitis C, multiple sclerosis and certain types of cancer.
+
IFNs were the first cytokines discovered more than half a century ago as agents that interfere with viral infection. Since then, IFNs have been established as pleiotropic, multifunctional proteins in the early immune response, exhibiting pronounced antiproliferative effects on cells, in addition to their strong immunomodulatory and antiviral activity. Due to their potency and diverse biological activities, IFNs are used for the treatment of several human diseases, including hepatitis C, multiple sclerosis and certain types of cancer.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All <scene name='User:David_Canner/Workbench/Opening_ifna/2'>type I IFNs</scene> initiate signaling by binding to the same receptor composed of two subunits called <scene name='User:David_Canner/Workbench/Opening_ifnar1/3'>IFNAR1</scene> and <scene name='User:David_Canner/Workbench/Opening_ifnar2/2'>IFNAR2</scene>. The intracellular domains (ICDs) of IFNAR1 and IFNAR2 are associated with the Janus kinases (Jaks) Tyk2 and Jak1, respectively (Figure 1A). Upon ligand binding by the IFNAR chains and formation of the signaling complex, these tyrosine kinases trans-phosphorylate and thereby activate each other. Subsequently, the activated Jaks phosphorylate STAT1, STAT2 and STAT3, which translocate into the nucleus and activate the transcription of hundreds of IFN-stimulated genes. To gain insight into how type I IFNs engage their receptor chains and how the receptor system is able to recognize the large number of different ligands, we determined the crystal structures of unliganded <scene name='User:David_Canner/Workbench/Opening_ifnar1_alone/2'>IFNAR1 (SD1 through SD3)</scene>, the binary complex <scene name='User:David_Canner/Workbench/Opening_ifnar2_binary/1'>between IFN-alpha-2 and IFNAR2</scene>, and the ternary ligand-receptor complexes of <scene name='User:David_Canner/Workbench/Opening_ternary_alpha/2'>IFN-alpha-2</scene> and <scene name='User:David_Canner/Workbench/Opening_ternary_gamma/3'>IFN-omega</scene> binding both receptor chains (Figure 1C). A final theoretical ternary structure including <scene name='User:David_Canner/Workbench/Opening_sd4_ternary/1'>IFNAR1-SD4</scene> was also created. These structures, in conjunction with biochemical experiments, reveal that the type I IFN receptor uses a mode of ligand interaction that is unique among cytokine receptors, but conserved between different IFNs.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All <scene name='User:David_Canner/Workbench/Opening_ifna/2'>type I IFNs</scene> initiate signaling by binding to the same receptor composed of two subunits called <scene name='User:David_Canner/Workbench/Opening_ifnar1/3'>IFNAR1</scene> and <scene name='User:David_Canner/Workbench/Opening_ifnar2/2'>IFNAR2</scene>. The intracellular domains (ICDs) of IFNAR1 and IFNAR2 are associated with the Janus kinases (Jaks) Tyk2 and Jak1, respectively (Figure 1A). Upon ligand binding by the IFNAR chains and formation of the signaling complex, these tyrosine kinases trans-phosphorylate and thereby activate each other. Subsequently, the activated Jaks phosphorylate STAT1, STAT2 and STAT3, which translocate into the nucleus and activate the transcription of hundreds of IFN-stimulated genes. To gain insight into how type I IFNs engage their receptor chains and how the receptor system is able to recognize the large number of different ligands, we determined the crystal structures of unliganded <scene name='User:David_Canner/Workbench/Opening_ifnar1_alone/2'>IFNAR1 (SD1 through SD3)</scene>, the binary complex <scene name='User:David_Canner/Workbench/Opening_ifnar2_binary/1'>between IFN-alpha-2 and IFNAR2</scene>, and the ternary ligand-receptor complexes of <scene name='User:David_Canner/Workbench/Opening_ternary_alpha/2'>IFN-alpha-2</scene> and <scene name='User:David_Canner/Workbench/Opening_ternary_gamma/3'>IFN-omega</scene> binding both receptor chains (Figure 1C). A final theoretical ternary structure including <scene name='User:David_Canner/Workbench/Opening_sd4_ternary/1'>IFNAR1-SD4</scene> was also created. These structures, in conjunction with biochemical experiments, reveal that the type I IFN receptor uses a mode of ligand interaction that is unique among cytokine receptors, but conserved between different IFNs.

Revision as of 22:07, 24 July 2011

Solved Structures of IFNAR1/2/IFN Complexes

Drag the structure with the mouse to rotate
  1. no reference


This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.
Personal tools